- Home
- AGEN vs ALEC Comparison
AGEN vs ALEC Comparison
Compare AGEN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ALEC
- Stock Information
- Founded
- AGEN 1994
- ALEC 2013
- Country
- AGEN United States
- ALEC United States
- Employees
- AGEN N/A
- ALEC N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGEN Health Care
- ALEC Health Care
- Exchange
- AGEN Nasdaq
- ALEC Nasdaq
- Market Cap
- AGEN 126.8M
- ALEC 124.0M
- IPO Year
- AGEN 2000
- ALEC 2019
- Fundamental
- Price
- AGEN $4.29
- ALEC $1.21
- Analyst Decision
- AGEN Buy
- ALEC Hold
- Analyst Count
- AGEN 2
- ALEC 9
- Target Price
- AGEN $14.50
- ALEC $3.40
- AVG Volume (30 Days)
- AGEN 460.1K
- ALEC 2.7M
- Earning Date
- AGEN 11-10-2025
- ALEC 11-06-2025
- Dividend Yield
- AGEN N/A
- ALEC N/A
- EPS Growth
- AGEN N/A
- ALEC N/A
- EPS
- AGEN N/A
- ALEC N/A
- Revenue
- AGEN $106,829,000.00
- ALEC $69,048,000.00
- Revenue This Year
- AGEN $60.49
- ALEC N/A
- Revenue Next Year
- AGEN N/A
- ALEC $314.69
- P/E Ratio
- AGEN N/A
- ALEC N/A
- Revenue Growth
- AGEN N/A
- ALEC 12.26
- 52 Week Low
- AGEN $1.38
- ALEC $0.87
- 52 Week High
- AGEN $7.34
- ALEC $4.18
- Technical
- Relative Strength Index (RSI)
- AGEN 54.02
- ALEC 32.72
- Support Level
- AGEN $4.17
- ALEC $1.16
- Resistance Level
- AGEN $4.60
- ALEC $1.60
- Average True Range (ATR)
- AGEN 0.28
- ALEC 0.13
- MACD
- AGEN 0.04
- ALEC 0.03
- Stochastic Oscillator
- AGEN 61.32
- ALEC 12.50
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.